A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer. Researchers discuss the findings.

Professor Park Joon-sik of obstetrics and gynecology at Soonchunhyang University Bucheon Hospital announced on the 14th that ...

One reason is the fact that much research related to ovarian cancer has focused on strategies ... urgent need to improve strategies to prolong survival, especially for all patients in a first ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies. CDK4/6 inhibitors show promise ...

While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer ... Overall survival data isn’t yet mature.

The study reveals that AI systems offer promising accuracy in predicting treatment outcomes, particularly when used to ...

ovarian cancer progressing under taxane/carboplatin chemotherapy or in early relapse (< 6 months).

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...